The steady and inexorable growth of the orphan drug market remains one of the prominent themes in the fourth edition of the EvaluatePharma Orphan Drug Report 2017.
What has changed in the last 12 months according to the report is the increased scrutiny of the price of these lifesaving products.
Key Highlights:
Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry.